Select an anorexigenic agent affecting serotoninergic system:

Correct Answer: A

Rationale: The correct answer is A: Fenfluramine. Fenfluramine is an anorexigenic agent that affects the serotoninergic system by increasing serotonin levels, leading to appetite suppression. It works by inhibiting the reuptake of serotonin, thereby increasing its availability in the brain. This mechanism helps in reducing food intake and promoting weight loss. Other choices - B: Fepranone, C: Desopimone, and D: Masindole - do not directly affect the serotoninergic system and are not known for their anorexigenic effects. Fepranone is a beta-adrenergic agonist, Desopimone is a dopamine reuptake inhibitor, and Masindole is a monoamine oxidase inhibitor. These mechanisms are not primarily associated with appetite suppression or weight loss.

Correct Answer: A

Rationale: The correct answer is A: Skeletal muscle weakness. Calcium channel blockers primarily affect smooth muscle in blood vessels and the heart, not skeletal muscles. Dizziness, headache, and flushing are common adverse effects due to vasodilation and reduced cardiac output. Therefore, the correct answer is A because skeletal muscle weakness is not a typical adverse effect of calcium channel blockers.

Correct Answer: C

Rationale: The correct answer is C: Angiotensin-converting enzyme inhibitors. These drugs inhibit the enzyme that breaks down bradykinin, leading to its accumulation. Ganglioblockers (A) and Alfa-adrenoblockers (B) do not directly affect bradykinin metabolism. Diuretics (D) primarily act on sodium and water balance, not bradykinin metabolism. In summary, C is correct as ACE inhibitors specifically inhibit bradykinin breakdown, while the other choices do not target this mechanism.

Correct Answer: D

Rationale: The correct answer is D because all three dopamine agonists, Bromocriptine, Cabergoline, and Pergolide, are known to decrease pituitary prolactin secretion. Dopamine inhibits prolactin release from the pituitary gland, and these agonists mimic dopamine's action. Therefore, all three choices are correct. Summary: A: Bromocriptine - Decreases pituitary prolactin secretion. B: Cabergoline - Decreases pituitary prolactin secretion. C: Pergolide - Decreases pituitary prolactin secretion. All choices are correct as they are dopamine agonists that decrease pituitary prolactin secretion.

Correct Answer: D

Rationale: Step 1: Estrogens are required for normal sexual maturation and growth of the female. This is true as estrogens play a key role in the development of secondary sexual characteristics and growth. Step 2: Estrogens decrease the rate of resorption of bone. This is true as estrogens help maintain bone density by inhibiting bone breakdown. Step 3: Estrogens enhance the coagulability of blood. This is true as estrogens can increase clotting factors leading to enhanced blood coagulability. Step 4: Combining the above points, it is evident that all the statements are true, making choice D the correct answer. Other choices are incorrect as they do not align with the established functions of estrogens.